Publication details

Ruxolitinib v léčbě primární myelofibrózy

Investor logo
Title in English Ruxolitinib in the treatment of primary myelofibrosis
Authors

ČERVINEK Libor DOUBEK Michael

Year of publication 2013
Type Article in Periodical
Magazine / Source Farmakoterapie
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.farmakoterapie.cz/c3631/ruxolitinib-v-lecbe-primarni-myelofibrozy
Field Oncology and hematology
Keywords Janus kinases; primary myelofibrosis; ruxolitinib
Attached files
Description Treatment of primary myeolofibrosis is still far from successful. This condition has the worst prognosis in the group of myeloproliferative disorders. The patients are very frequently in advanced age and cannot therefore be offered allogeneic bone marrow transplantation.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info